Answers are grounded in this paper and cite their sources.
Even though the overall number of MSI-H CCAs is low, the dismal prognosis of the disease and the therapeutic option of immune checkpoint blockade in the respective patients justify MSI testing of cholangiocarcinoma, particularly in younger patients showing an atypical histomorphology.
No takes yet. Share an insight, caveat, or question.
Goeppert et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: